• The use of an aromatase inhibitor (letrozole) with an inhibitor of the cyclin dependent kinases 4 and 6 (ribociclib):
    • Was compared with aromatase inhibitor alone in postmenopausal women with hormone receptor positive, HER2-negative metastatic breast cancer:
      • In the MONALEESA-2 study:
        • Results showed an improvement in:
          • Progression-free survival (PFS):
            • From 42.2% to 63%
          • Overall response rate:
            • From 37.1% to 52.7%
              • With the addition of ribociclib to letrozole alone
  • This regimen was also investigated in pre menopausal women with advanced, hormone receptor-positive breast cancer:
    • Improved PFS compared with placebo plus endocrine therapy
  • References:
    • Hortobagi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18)1738-1748.
    • Tripathy D, Im SA2, Colleoni M3, Franke F4, Bardia A5, Harbeck Nm et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915.

#Arrangoiz #CancerSurgeon #BreastSurgeon #BreastCancer #Monaleesa2 #Ribociclib #CASO #CenterforADvancedSurgicalOncology

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s